NTLA Intellia Therapeutics, Inc.
NTLA Intellia Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 2 scans as of 2026-08-17 1 bear 1 neutral converging
POC $13.45 · VWAP $13.67 · -11.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
4 watchlists
NTLA Price Structure
Loading timeframes…
Peers
Every watchlist NTLA belongs to, members best 30-day change first — NTLA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@ibb
@biotech-scan
@insider-universe
Reported the quarter ending 2026-03-31: revenue $15M, diluted EPS $-0.81, net income $-96M (SEC filing). Across the print the stock moved +1.7% (close before → first close after).
full note →Against street estimates
How NTLA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about NTLA from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 19 days ago · Jul 30
- Intellia Therapeutics (NTLA) Stock Price & Overview
- Intellia Therapeutics - NTLA - Stock Price Today - Zacks
- Intellia Therapeutics, Inc. (NTLA) Latest Stock News ...
- Should You Buy or Sell Intellia Therapeutics Stock? Get The Latest NTLA Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.
- Intellia Therapeutics (NTLA) Investor Relations, Earnings ...
NTLA research tape
80 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to NTLA.
NTLA — watch above $18.50